Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Benefits of trastuzumab are lasting, reducing both HER2 + breast cancer deaths and recurrence

05.06.2007
An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

These studies, sponsored by the National Cancer Institute (NCI), were undertaken to test whether trastuzumab adds to the benefit of adjuvant chemotherapy (doxorubicin, known as Adriamycin, and cyclophosphamide) followed by paclitaxel (Taxol) in women with HER2 + breast cancer who have undergone surgery. Trastuzumab treats the approximately 20 percent of tumors that are HER2 +, that is, their cancer makes too much of the surface protein HER2, which tends to make the cancer grow faster and recur more often than tumors that are not HER2 +.

Four years of follow-up data have concluded that 85.9 percent of 1,989 women treated with trastuzumab are cancer free and 92.6 percent are alive, compared with 73.1 percent and 89.4 percent, respectively, of 1,979 women who were not treated with the monoclonal antibody. In all, 397 patients in the chemotherapy group have developed a recurrent tumor or have died, compared to only 222 in the trastuzumab group.

These results mean that the hazard of disease recurrence is decreased by 52 percent with the addition of trastuzumab to chemotherapy and that trastuzumab therapy was associated with a 35 percent reduction in the risk of death, according to Edith Perez, M.D., director of Mayo Clinic’s Multidisciplinary Breast Clinic in Jacksonville, Fla., and primary investigator of one of the trials. She is presenting results of the joint analysis at the annual meeting of the American Society of Clinical Oncology (ASCO).

“Trastuzumab has revolutionized the care of HER2 + breast cancer, and this study clearly shows the statistical and clinical significance of the therapy,” says Dr. Perez.

The four-year data show a persistent benefit compared to what was seen at two years, according to Dr. Perez, with trastuzumab combined with chemotherapy continuing to outperform chemotherapy treatment alone. The first joint analysis of these two trials, published Oct. 20, 2005, in the New England Journal of Medicine, showed that at a median of two years after treatment, disease-free survival and overall survival were improved by 52 percent and 33 percent, respectively, with addition of trastuzumab. “The new data are important as they document the continued benefit of the targeted therapy,” she says. Targeted therapy uses a specific agent directed against a particular change in a cancer cell.

Researchers also found that the highest risk of relapse occurs within the first two years, and that recurrences continue to occur with longer follow-up. Breast cancer is also more likely to return in patients who were initially diagnosed with larger tumors, or whose cancer was discovered to have spread to a number of lymph nodes, or who had HER2 + cancer that was further sub-typed as estrogen receptor (ER)-negative. So far, 118 patients in the trastuzumab treatment group have developed progressive disease, a second primary cancer or contralateral breast cancer (cancer in the other breast), compared with 243 patients in the chemotherapy group.

In one of the trials (NCCTG-N9831), Dr. Perez reports that the risk of weakened heart muscle was greater in the trastuzumab-treated group compared to patients receiving just chemotherapy (2.5 percent versus 0.2 percent), including cases of congestive heart failure (22 versus 1). But the only cardiac death occurred in the chemotherapy group, she says. “We have learned that cardiac toxicity that might result from trastuzumab can be managed in most cases,” she says.

Dr. Perez says that continuing follow-up is needed to continue to define the long-term benefit of using trastuzumab in these patients.

Trastuzumab was approved for the treatment of advanced breast cancer in 1998.

The clinical trials, known as NCCTG-N9831 and NSABP-B-31, were conducted by a network of researchers led by the North Central Cancer Treatment Group (NCCTG) and the National Surgical Adjuvant Breast and Bowel Project (NSABP), in collaboration with the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Dr. Perez led NCCTG-N9831, as well as the updated analysis.

According to the American Cancer Society, about 178,480 women in the United States will be diagnosed with invasive breast cancer in 2007. About 40,460 women will die from the disease this year. Right now, more than 2 million women living in the United States have been treated for breast cancer.

Nancy Jensen | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>